Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.94 |
| ▸ | PRKCG | P05129 | 5/20 | 0.91 |
| ▸ | PRKCB | P05771 | 5/20 | 0.91 |
| ▸ | PRKCH | P24723 | 5/20 | 0.91 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.91 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.91 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.91 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.91 |
| ▸ | PRKCI | P41743 | 4/20 | 0.91 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.91 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.91 |
| ▸ | USP2 | O75604 | 2/20 | 0.91 |
| ▸ | TP53 | P04637 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 1/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211990 | 1.00 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL1568997 | 1.00 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL2411275 | 0.99 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL31109155 | 0.99 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL18399995 | 0.99 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL1893793 | 0.95 | PRKCA (0.89) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL6844180 | 0.95 | PRKCA (0.89) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| Phorbol Myristate Acetate SCHEMBL19271683 | 0.95 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| Phorbol Myristate Acetate SCHEMBL115567 | 0.95 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| Phorbol Myristate Acetate SCHEMBL22736719 | 0.95 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| US-12539289-B2 | Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia | BIOSUCCESS BIOTECH COMPANY, LIMITED (US) | 2026-02-03 | — | — | US | claimed |
| EP-2804601-B1 | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases | BIOSUCCESS BIOTECH CO LTD (US) | 2025-04-02 | — | — | EP | claimed |
| US-20240261247-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | BIOSUCCESS BIOTECH CO., LTD. (US) | 2024-08-08 | — | — | US | claimed |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2024-03-14 | — | — | US | claimed |
| EP-4304570-A2 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES | Phor-Med, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-20230277495-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | BIOSUCCESS BIOTECH CO. LTD. (US) | 2023-09-07 | — | — | US | claimed |
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | PHOR-MED, INC. | 2023-08-10 | — | — | US | claimed |
| US-11696908-B2 | Compositions and methods of use of phorbol esters | BIOSUCCESS BIOTECH CO. LTD. (US) | 2023-07-11 | — | — | US | claimed |
| EP-2804669-B1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE | BIOSUCCESS BIOTECH CO LTD (US) | 2023-03-29 | — | — | EP | claimed |
| US-20080153780-A1 | Use Of A Vanilloid Receptor Agonist Together With A Glycosaminoglycan Or Proteoglycan For Producing An Agent For Treating Articular Pains And Method For Applying Said Agent | MESTEX AG (CH) | 2008-06-26 | — | — | US | claimed |
| EP-1830835-A1 | USE OF A VANILLOID RECEPTOR AGONIST TOGETHER WITH A GLYCOSAMINOGLYCAN OR PROTEOGLYCAN FOR PRODUCING AN AGENT FOR TREATING ARTICULAR PAINS AND METHOD FOR APPLYING SAID AGENT | Mestex AG (CH) | 2007-09-12 | — | — | EP | claimed |
| WO-2006069452-A1 | USE OF A VANILLOID RECEPTOR AGONIST TOGETHER WITH A GLYCOSAMINOGLYCAN OR PROTEOGLYCAN FOR PRODUCING AN AGENT FOR TREATING ARTICULAR PAINS AND METHOD FOR APPLYING SAID AGENT | MESTEX AG (CH) | 2006-07-06 | — | — | WO | claimed |
| US-20050095579-A1 | Methods for diagnosing bipolar and unipolar disorder | FREE STATE DIAGNOSTICS, INC. | 2005-05-05 | — | — | US | claimed |
| EP-0966523-A1 | METHOD FOR THE PRODUCTION OF SELECTED LYMPHOCYTES | HEMOSOL INC. (CA) | 1999-12-29 | — | — | EP | claimed |
| WO-1998033891-A1 | METHOD FOR THE PRODUCTION OF SELECTED LYMPHOCYTES | HEMOSOL INC. (CA) | 1998-08-06 | — | — | WO | claimed |
| EP-0752867-A4 | SELECTIVE CELL PROLIFERATION | HEMOSOL INC (CA) | 1997-07-23 | — | — | EP | claimed |
| EP-0752867-A1 | SELECTIVE CELL PROLIFERATION | HEMOSOL INC. (CA) | 1997-01-15 | — | — | EP | claimed |
| WO-1994016715-A1 | SELECTIVE CELL PROLIFERATION | HEMOSOL, INC. (CA) | 1994-08-04 | — | — | WO | claimed |
| US-4760021-A | culturing, separating microphase-like cells, activating with mitogen, isolating | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1988-07-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696908-B2 | Compositions and methods of use of phorbol esters | PMAIP1, CD38, PKD1 | PRKCA 41/4885PRKCG 53/4885PRKCB 58/4885 |
| US-20240261247-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | PMAIP1, KLK3, ACP3 | PRKCA 42/4885PRKCG 51/4885PRKCB 62/4885 |
| US-20230277495-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | PMAIP1, KLK3, ACP3 | PRKCA 42/4885PRKCG 51/4885PRKCB 62/4885 |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | TSLP, MAVS, PLAA | PRKCA 32/4885PRKCG 102/4885PRKCB 115/4885 |
| US-12539289-B2 | Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia | MYD88, EBP, IL2 | PRKCA 45/4885PRKCG 154/4885PRKCB 37/4885 |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | MAVS, ACE2, PLAA | PRKCA 12/4885PRKCG 36/4885PRKCB 70/4885 |
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | MAVS, ACE2, CCL11 | PRKCA 16/4885PRKCG 34/4885PRKCB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.